Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

$24.99

Economic Value Added (EVA)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Regeneron Pharmaceuticals Inc., economic profit calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The analysis of financial data reveals notable fluctuations and trends over the five-year period examined.

Net Operating Profit After Taxes (NOPAT)
NOPAT shows significant variations, with a peak in 2021 at approximately 7.82 billion US dollars, followed by a substantial decline to around 2.82 billion in 2023. There is a moderate recovery to about 3.37 billion in 2024, though it remains below the peak observed in 2021. This indicates periods of strong operational performance followed by challenges in maintaining high profitability.
Cost of Capital
The cost of capital remains relatively stable over the period, with slight incremental increases from 5.52% in 2020 to a peak of 5.64% in 2023, then a marginal decrease to 5.62% in 2024. This stability suggests consistent market-based expectations of risk and return for the company’s invested capital.
Invested Capital
Invested capital demonstrates a steady upward trend, increasing from approximately 8.42 billion US dollars in 2020 to 12.65 billion in 2024. This growth reflects ongoing investments or accumulation of assets to support the company’s operations and growth strategies.
Economic Profit
Economic profit trends closely mirror those of NOPAT, with a peak in 2021 near 7.22 billion US dollars, followed by declines in subsequent years to a low of about 2.15 billion in 2023 and a partial rebound to 2.66 billion in 2024. This pattern suggests that despite increased invested capital, the returns above cost of capital have fluctuated substantially, highlighting variations in value generation for shareholders over time.

Overall, the financial data indicates that the company experienced its strongest operational and economic profitability in 2021, but faced challenges in sustaining that level in the following years. Increased invested capital combined with declining economic profit after 2021 suggests that returns did not keep pace with capital growth, impacting value creation. However, the slight recovery in 2024 points to potential stabilization or improvement in profitability moving forward.


Net Operating Profit after Taxes (NOPAT)

Regeneron Pharmaceuticals Inc., NOPAT calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net income
Deferred income tax expense (benefit)1
Increase (decrease) in deferred revenue2
Increase (decrease) in equity equivalents3
Interest expense
Interest expense, operating lease liability4
Adjusted interest expense
Tax benefit of interest expense5
Adjusted interest expense, after taxes6
(Gain) loss on marketable securities
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income7
Investment income, after taxes8
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in deferred revenue.

3 Addition of increase (decrease) in equity equivalents to net income.

4 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

5 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

6 Addition of after taxes interest expense to net income.

7 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

8 Elimination of after taxes investment income.


Net Income Trend
The net income exhibited significant volatility over the five-year period. It increased markedly from approximately $3.51 billion in 2020 to a peak of $8.08 billion in 2021. However, in the subsequent years, net income declined sharply to about $4.34 billion in 2022 and further declined to $3.95 billion in 2023. There was a moderate recovery observed in 2024, with net income increasing to roughly $4.41 billion.
Net Operating Profit After Taxes (NOPAT) Trend
The NOPAT also showed a similar pattern of fluctuation. Starting at approximately $3.70 billion in 2020, it rose significantly to around $7.82 billion in 2021. After this peak, NOPAT experienced a marked decrease to about $3.55 billion in 2022, continuing its downward trend to approximately $2.82 billion in 2023. A slight improvement is noted in 2024, where NOPAT increased to nearly $3.37 billion.
Comparative Analysis Between Net Income and NOPAT
Both net income and NOPAT followed parallel trajectories, with substantial growth in 2021 followed by pronounced declines in 2022 and 2023, and moderate recovery in 2024. Notably, the decline in NOPAT after 2021 was somewhat steeper than the decline in net income, particularly between 2022 and 2023. Despite the fluctuations, net income consistently remained slightly lower than NOPAT throughout the period, indicating possible differences in non-operating income, expenses, or tax effects.
General Insights
The data reveals a peak in profitability metrics in 2021, suggestive of exceptional performance or favorable conditions during that year. The subsequent deterioration through 2022 and 2023 may imply operational challenges, increased expenses, or adverse market conditions impacting operational efficiency and profitability. The modest rebound in 2024 suggests some recovery, though neither net income nor NOPAT returned to the peak levels observed in 2021.

Cash Operating Taxes

Regeneron Pharmaceuticals Inc., cash operating taxes calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Income tax expense
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The financial data reveals notable fluctuations in tax-related expenses over the five-year period under review. Income tax expense and cash operating taxes show varying trends that indicate changes in the company’s profitability, tax strategies, or regulatory environment impacts.

Income Tax Expense
This item increased substantially from 297,200 thousand US dollars in 2020 to a peak of 1,250,500 thousand US dollars in 2021, representing a more than fourfold increase. The subsequent years show a marked decrease to 520,400 thousand US dollars in 2022 and further declines to 245,700 thousand US dollars in 2023. In 2024, there was a modest recovery to 367,300 thousand US dollars. These changes suggest significant variations in taxable income or effective tax rates year over year.
Cash Operating Taxes
Cash operating taxes exhibit a different pattern. Starting at 212,370 thousand US dollars in 2020, these taxes surge to 1,400,760 thousand US dollars in 2021, exceeding the income tax expense increase, which may indicate timing differences or adjustments in tax payments versus accruals. Unlike income tax expense, cash operating taxes peaked in 2022 at 1,246,398 thousand US dollars, only slightly decreasing thereafter to 995,682 thousand US dollars in 2023 and stabilizing around 989,515 thousand US dollars in 2024. This suggests that cash payments for taxes remained relatively high and steady after the initial spike in 2021.

Overall, the data points to a significant tax-related financial impact in 2021 followed by a normalization trend in subsequent years, though cash operating taxes remained at elevated levels compared to 2020. The divergence between income tax expense and cash operating taxes in later years could reflect changes in deferred tax assets or liabilities, timing differences, or tax planning strategies.


Invested Capital

Regeneron Pharmaceuticals Inc., invested capital calculation (financing approach)

US$ in thousands

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Finance lease liabilities, current portion
Long-term debt
Finance lease liabilities, excluding current portion
Operating lease liability1
Total reported debt & leases
Stockholders’ equity
Net deferred tax (assets) liabilities2
Deferred revenue3
Equity equivalents4
Accumulated other comprehensive (income) loss, net of tax5
Adjusted stockholders’ equity
Construction in progress6
Marketable securities7
Invested capital

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of deferred revenue.

4 Addition of equity equivalents to stockholders’ equity.

5 Removal of accumulated other comprehensive income.

6 Subtraction of construction in progress.

7 Subtraction of marketable securities.


Total Reported Debt & Leases
The total reported debt and leases remained relatively stable from 2020 to 2023, fluctuating slightly around the 2.76 to 2.79 billion US dollars range. In 2024, there was a noticeable increase to approximately 2.94 billion, indicating a rise in the company's leverage or financing obligations during that year.
Stockholders’ Equity
Stockholders’ equity showed a strong and consistent upward trend across the entire period. Starting at about 11.03 billion in 2020, it increased significantly each year, reaching nearly 29.35 billion by the end of 2024. This growth suggests robust retained earnings and possibly additional equity financing, reflecting an overall strengthening in the company’s net worth and financial position.
Invested Capital
Invested capital experienced growth from 8.42 billion in 2020 to a peak of approximately 12.29 billion in 2022. However, a decline followed in 2023, dropping to about 12.00 billion, before rising again to roughly 12.65 billion in 2024. This pattern indicates a moderate fluctuation in the capital deployed within the business, which could be related to changes in assets or operational investments during the period.

Cost of Capital

Regeneron Pharmaceuticals Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Long-term debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and finance lease liabilities. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Long-term debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and finance lease liabilities. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Long-term debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and finance lease liabilities. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Long-term debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and finance lease liabilities. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Long-term debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and finance lease liabilities. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Regeneron Pharmaceuticals Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


Economic Profit Trends
The economic profit exhibited notable fluctuations over the reviewed periods. Starting at approximately $3.2 billion, it more than doubled in the subsequent period to around $7.2 billion. However, this was followed by a significant decline to about $2.9 billion and further decreased to roughly $2.1 billion. In the latest period, a modest recovery is observed with the economic profit rising again to approximately $2.7 billion. This pattern suggests volatility in profitability, with a peak followed by a period of contraction and a slight resurgence.
Invested Capital Development
Invested capital showed a consistent upward trend throughout the periods. Beginning at approximately $8.4 billion, it steadily increased each year to about $10.8 billion, then $12.3 billion, slightly dipping to $12.0 billion, before increasing again to $12.7 billion. This overall growth indicates ongoing investment activities and expansion of the capital base, with only a minor contraction in the fourth period.
Economic Spread Ratio Analysis
The economic spread ratio, which measures the value created relative to invested capital, also displayed considerable variability. Initially recorded at 38.43%, it surged significantly to nearly 67% in the second period, indicating highly efficient capital utilization. However, the ratio subsequently dropped sharply to approximately 23.24%, followed by a decrease to 17.89%. The last period shows a partial improvement to 21.05%. These shifts parallel the changes in economic profit and suggest that capital efficiency reached a peak early on, then declined, and is now showing signs of recovery.
Overall Insights
The data reflect a dynamic operational environment with periods of strong profitability and effective capital use, followed by downturns. While invested capital has generally expanded, economic profit and the related economic spread ratio have not consistently followed, indicating potential challenges in maintaining high returns on new investments. The recent modest improvements in economic profit and spread ratio may suggest early indications of operational adjustments or market conditions improving.

Economic Profit Margin

Regeneron Pharmaceuticals Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Economic profit1
 
Revenues
Add: Increase (decrease) in deferred revenue
Adjusted revenues
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted revenues
= 100 × ÷ =

3 Click competitor name to see calculations.


The company's financial data over the five-year period shows notable fluctuations in economic profit, adjusted revenues, and economic profit margin.

Economic Profit
The economic profit increased significantly from 3,237,428 thousand US dollars in 2020 to a peak of 7,219,881 thousand US dollars in 2021. Following this peak, there was a marked decline in 2022 to 2,855,793 thousand US dollars, continuing to decrease in 2023 to 2,146,268 thousand US dollars. In 2024, the economic profit showed a slight recovery, rising to 2,663,801 thousand US dollars. This pattern indicates volatility with a peak in 2021 followed by a downward trend and partial rebound.
Adjusted Revenues
The adjusted revenues demonstrated a strong upward trajectory initially, nearly doubling from 8,645,200 thousand US dollars in 2020 to 15,951,500 thousand US dollars in 2021. However, revenues dropped considerably in 2022 to 12,205,300 thousand US dollars. Thereafter, the revenue experienced a moderate recovery, rising to 13,155,100 thousand US dollars in 2023 and further to 14,429,800 thousand US dollars in 2024, though not reaching the 2021 peak again within the period.
Economic Profit Margin
The economic profit margin followed a similar trend to economic profit. It increased from 37.45% in 2020 to a high of 45.26% in 2021. This was followed by a notable decrease to 23.4% in 2022 and a further decline to 16.32% in 2023. The margin improved to 18.46% in 2024 but remained well below the peak levels of 2021. This suggests declining efficiency or profitability relative to revenues after 2021, with some improvement in the final year observed.

Overall, the data reveal a peak in company performance in 2021 across all metrics, followed by a period of decline. Despite moderate recovery in 2023 and 2024, the economic profit, revenues, and profit margin have not returned to the peak levels recorded in 2021, indicating potential challenges in sustaining prior growth momentum or profitability levels.